Eletriptan Impurities and Eletriptan
Daicel Pharma offers high-quality impurities for Eletriptan, an active pharmaceutical ingredient. These impurities, including Eletriptan Impurity 10, Eletriptan Impurity 8, and Eletriptan Impurity 9, play a vital role in assessing Eletriptan purity, reliability, and safety. Daicel Pharma also offers a customized synthesis of Eletriptan impurities to cater to client requirements, with worldwide delivery options available.
Eletriptan [CAS: 143322-58-1], developed by Pfizer Inc, is a second-generation triptan drug designed to alleviate migraine headaches. It acts as a serotonergic agonist, exerting vasoconstrictor effects, and also possesses properties of a non-steroidal anti-inflammatory drug.
Eletriptan: Use and Commercial Availability
Eletriptan, available under Relpax, is an indole compound for treating migraines in adults with or without aura. It interacts with drugs metabolized by cytochrome P-450, including CYP-3A4.
Eletriptan Structure and Mechanism of Action
The chemical name of Eletriptan is 3-[[(2R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole. Its chemical formula is C22H26N2O2S, and its molecular weight is approximately 382.5 g/mol.
Eletriptan binds to o 5-HT1B, 5-HT1D, and 5-HT1F receptors located on intracranial blood vessels, leading to vasoconstriction and relief of migraine headaches.
Eletriptan Impurities and Synthesis
The analysis and control of impurities in Eletriptan, a migraine medication, are crucial to ensure its quality and safety. Various techniques such as chromatography, spectroscopy, and mass spectrometry help identify and quantify impurities. Impurity profiling helps determine their chemical composition, structure, and toxicity. Strict control measures during the manufacturing process1 help minimize impurity formation, and regulatory guidelines specify acceptable limits for impurities in pharmaceutical products. Thorough analysis and effective control of Eletriptan impurities contribute to their quality and efficacy for patient use.
Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for Eletriptan impurity standards, including Eletriptan Impurity 10, Eletriptan Impurity 8, and Eletriptan Impurity 9. They generate from an analytical facility that complies with cGMP standards. The CoA provides a detailed characterization report with data obtained through techniques such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity analysis. We give additional data like 13C-DEPT upon request. Daicel Pharma synthesizes unknown Eletriptan impurities or degradation products. Every delivery has a complete characterization report.
- Macor, John Eugene; Wythes, Martin James, Indole Derivatives, Pfizer Inc., United States, EP592438B1, August 27, 1997
- Singh, Pradeep Kumar; Dinda, Subas Chandra, Development and validation of a stability indicating RP-HPLC method for determination of Eletriptan in Eletriptan Hydrobromide orally disintegrating tablets, International Research Journal of Pharmacy, Volume: 4, Issue: 6, Pages: 179-182, 2013
Frequently Asked Questions
Impurities in Eletriptan can harm the drug's safety, efficacy, and stability. Therefore, it is essential to identify, characterize, and control these impurities to ensure the quality of the medication.
The synthesis of Eletriptan involves several chemical reactions and purification steps to obtain the desired drug molecule. It is vital to optimize the synthetic process to minimize impurity formation.
The quality of Eletriptan is ensured through rigorous quality control measures, including the analysis and control of impurities. Regulatory guidelines define acceptable limits for impurities for manufacturers to adhere to these standards.
Methanol or Acetonitrile are the solvents used for analyzing many impurities in Eletriptan.
Eletriptan impurities are stored at a controlled room temperature of 2-8 °C or according to the Certificate of Analysis (CoA) specifications.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.